Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: A critical assessment based on recently reported phase III trials in colorectal and breast cancer

Journal of Clinical Oncology

Volumn 21, Issue 10, 2003, Pages 2045-2047

  Di Leo, Angelo ^a   Bleiberg, Harry ^a   Buyse, Marc ^b  

^a JULES BORDET INSTITUTE   (Belgium)

^b International Drug Development Institute (IDDI)   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST TUMOR; COLORECTAL TUMOR; EPIDEMIOLOGY; HUMAN; LETTER; METASTASIS; MORTALITY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; SURVIVAL; TREATMENT OUTCOME;

BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III; COLORECTAL NEOPLASMS; CONFOUNDING FACTORS (EPIDEMIOLOGY); HUMANS; NEOPLASM METASTASIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0037674049     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2003.99.089     Document Type: Letter

References (14)

1. U.S. Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research. Guidance for Industry. Http://www.fda.gov/cder/guidance/index.htm
2. The European Agency for the Evaluation of Medicinal Products (EMEA). Note for guidance on evaluation of anticancer medicinal products in man. Http://www.emea.eu.int
3. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
4. Giacchetti S, Perpoint B, Zidani R, et al: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracilleucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136-147, 2000
5. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicenter randomised trial. Lancet 335: 1041-1047, 2000
6. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905-914, 2000
7. Jassem J, Pienkowski T, Pluzanska A, et al: Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: Final results of a randomized phase III multicenter trial. J Clin Oncol 19:1707-1715, 2001
8. Biganzoli L, Cufer T, Bruning P, et al: Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial. J Clin Oncol 20:3114-3121, 2002
9. Luck HJ, Thomssen C, Untch M, et al: Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC). Epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC). A study of the AGO Breast Cancer Group. Proc Am Soc Clin Oncol 19:73, 2000 (abstr 280)
10. Carmichael J: UKCCCR trial of epirubicin and cyclophosphamide (EC) vs. epirubicin and Taxol (ET) in the first line treatment of women with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 20:22, 2001 (abstr 84)
11. Nabholtz JM, Falkson G, Campos D, et al: A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first-line chemotherapy for MBC. Proc Am Soc Clin Oncol 18:127, 1999 (abstr 485)
12. Mackey JR, Paterson A, Dirix LY, et al: Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 21:35, 2002 (abstr 137)
13. Bonneterre J, Dieras V, Tubiana-Hulin M, et al: 6 cycles of epirubicin/docetaxel (ET) versus 6 cycles of 5FU epirubicin/cyclophosphamide (FEC) as first-line metastatic breast cancer (MBC) treatment. Proc Am Soc Clin Oncol 20:42, 2001 (abstr 163)
14. Mouridsen H, Gershanovich M, Sun Y, et al: Superior efficacy of letrozole (Femara) versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596-2606, 2001